A Study of LY3526318 in Healthy Women

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 12, 2019

Primary Completion Date

February 28, 2020

Study Completion Date

March 6, 2020

Conditions

Healthy

Interventions

DRUG

LY3526318

Administered orally.

DRUG

Placebo

Administered orally.

Trial Locations (1)

Universitaire Ziekenhuizen Leuven - Campus Gasthuisberg, Leuven

All Listed Sponsors

lead

Eli Lilly and Company

INDUSTRY

NCT04183283 - A Study of LY3526318 in Healthy Women | Biotech Hunter | Biotech Hunter